SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Rights Issue
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
3/21/2025
Diamyd Medical announces additional subscription commitments for upcoming rights issue
3/19/2025
Diamyd Medical plans for GMP Certification in 2025
3/17/2025
Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025
3/13/2025
Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project
3/10/2025
Diamyd Medical announces additional subscription commitments for upcoming rights issue
2/28/2025
The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million
2/20/2025
Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico
2/18/2025
Diamyd Medical’s CFO to leave in 2025
2/12/2025
Diamyd Medical announces expanded financial support from Breakthrough T1D
1/29/2025
Quarterly Report 1 24/25
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research